CIBC Private Wealth Group LLC Reduces Stock Holdings in CVS Health Corporation $CVS

CIBC Private Wealth Group LLC cut its position in shares of CVS Health Corporation (NYSE:CVS) by 17.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,357 shares of the pharmacy operator’s stock after selling 11,046 shares during the period. CIBC Private Wealth Group LLC’s holdings in CVS Health were worth $3,947,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Howe & Rusling Inc. acquired a new position in CVS Health in the second quarter valued at approximately $210,000. Dynamic Technology Lab Private Ltd acquired a new stake in CVS Health during the second quarter worth $562,000. Prudential PLC lifted its stake in shares of CVS Health by 58.9% in the 2nd quarter. Prudential PLC now owns 28,856 shares of the pharmacy operator’s stock valued at $1,990,000 after purchasing an additional 10,691 shares during the last quarter. Handelsbanken Fonder AB lifted its stake in shares of CVS Health by 1.5% in the 2nd quarter. Handelsbanken Fonder AB now owns 592,867 shares of the pharmacy operator’s stock valued at $40,896,000 after purchasing an additional 8,653 shares during the last quarter. Finally, Swiss National Bank grew its holdings in shares of CVS Health by 7.7% during the 2nd quarter. Swiss National Bank now owns 3,821,360 shares of the pharmacy operator’s stock worth $263,597,000 after purchasing an additional 272,100 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Stock Performance

Shares of CVS Health stock opened at $71.58 on Friday. The business has a 50-day simple moving average of $77.48 and a 200-day simple moving average of $77.81. The company has a market cap of $91.07 billion, a PE ratio of 51.87, a P/E/G ratio of 0.75 and a beta of 0.49. CVS Health Corporation has a one year low of $58.35 and a one year high of $85.15. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The company had revenue of $105.69 billion during the quarter, compared to the consensus estimate of $103.67 billion. During the same quarter in the previous year, the firm earned $1.19 earnings per share. The firm’s quarterly revenue was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, equities research analysts forecast that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd will be given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.7%. The ex-dividend date of this dividend is Thursday, April 23rd. CVS Health’s payout ratio is 192.75%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CVS. Sanford C. Bernstein upgraded shares of CVS Health from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $91.00 to $94.00 in a report on Thursday, March 12th. UBS Group reissued an “outperform” rating on shares of CVS Health in a research note on Wednesday, December 10th. Barclays lifted their target price on shares of CVS Health from $87.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Wolfe Research lowered their price target on CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a research report on Monday, March 2nd. Finally, Bank of America cut their price objective on CVS Health from $100.00 to $95.00 and set a “buy” rating on the stock in a report on Tuesday, January 27th. Twenty investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $95.05.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS’s board declared a quarterly dividend of $0.665/share (payable May 4; record April 23), a cash-return signal that can support the share price. CVS Health declares quarterly dividend
• Positive Sentiment: Brokerages’ consensus rating sits at “Moderate Buy,” providing analyst support amid volatility. CVS Health Corporation (NYSE:CVS) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Positive Sentiment: CVS announced a $2.24M investment to expand health access in west Charlotte — a community-health initiative that highlights growth of care-delivery and outreach programs. CVS Health invests $2.24 million in west Charlotte health initiative
• Neutral Sentiment: Media roundup and dividend-focused pieces are covering CVS alongside other dividend payers — keeps the name in income-focused investor conversations but is unlikely to move shares materially. Dividend roundup: JPMorgan Chase, Micron Technology, CVS Health, Broadcom, and more
• Neutral Sentiment: Coverage calling CVS a “trending” stock and roundups on healthcare stock picks keep investor attention but are mixed in tone — watch for conviction from earnings/forward guidance. CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Company exec discussed AI policy and quality initiatives — signals operational focus but not an immediate catalyst. CVS Health/Aetna executive discusses company AI policy and the harder truth about quality
• Negative Sentiment: Bernstein Litowitz filed a racketeering class action against CaremarkPCS and CVS alleging fraud of PBM customers — this is a material legal overhang that could prompt costs, fines or settlements. Bernstein Litowitz Berger & Grossmann Announces Filing of Racketeering Class Action Against CaremarkPCS and CVS Health Corporation
• Negative Sentiment: Tennessee legislation targeting pharmacy benefit managers (PBMs) could force store closures — state estimates say 100+ CVS locations might be affected, raising local revenue and access risks. TN bill targeting pharmacy benefit managers could threaten closure of 100+ CVS stores in the state
• Negative Sentiment: Lawmakers and a U.S. Representative (Aftyn Behn) are calling for investigations and have heard conflicting testimony about CVS claims that pharmacies will close — increased regulatory scrutiny and political risk. Rep. Aftyn Behn calls for an investigation into CVS claims that pharmacies are closing
• Negative Sentiment: Local reporting and commentary examine whether lawmakers can curb CVS/PBM influence on drug pricing — signals broader regulatory attention on CVS’s PBM business. Could lawmakers crack CVS’s grip on the prescription drug supply chain?

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.